Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 24.70

From 52W high−46.45%

Volume1.56M

Market capCNY 3.46B

P/E (TTM)−84.2x

P/S (TTM)9.6x

Div yield—

Key dataSep 18, 2026

Open

CNY 24.70

From 52W high

−46.45%

Volume

1.56M

Market cap

CNY 3.46B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

64.9x

P/E (TTM)

−84.2x

RSI (14)

36.1

MomentumView details →

1D Return

−2.76%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−84.2x

EV/EBITDA

64.9x

EV/Sales

9.7x

P/S (TTM)

9.6x

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

63.55%

Net Margin

−10.05%

EBITDA Margin

14.98%

ROE (TTM)

−1.11%

ROA (TTM)

−0.89%

Asset Turnover

0.09x

GrowthView details →

Revenue YoY

−6.88%

EPS YoY

−36.99%

FCF YoY

—

Revenue CAGR 3Y

−60.58%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−2.76%

YTD Return

—

1Y Return

—

RSI (14)

36.1

vs 50D SMA

−10.12%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

3.33x

Quick Ratio

3.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

−49.68%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

326.02M

Net Income (TTM)

−32.78M

Op. CF (TTM)

23.43M

Latest newsMore news →

Suzhou Sursen Biopharmaceutical Co., Ltd. announced its 2026 first-half results: net profit attributable to shareholders was 19.5646 million yuan, up 390.02% year-on-year, with revenue of 147 million yuan, down 16.03%.24d ago

Similar companies

Shanghai Haohai Biological Technology Co., Ltd.06826.HK Legend Biotech CorporationLEGN Viking Therapeutics, Inc.VKTX 普莱柯603566.SH Enliven Therapeutics, Inc.ELVN 申联生物688098.SH Find similar companies →

Latest newsMore news →

Suzhou Sursen Biopharmaceutical Co., Ltd. announced its 2026 first-half results: net profit attributable to shareholders was 19.5646 million yuan, up 390.02% year-on-year, with revenue of 147 million yuan, down 16.03%.24d ago